{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:14:16Z","timestamp":1761174856113,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012130","name":"Blue Cross and Blue Shield of Louisiana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008125","name":"Humana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000992","name":"Baton Rouge Area Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cmi.2020.12.029","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T11:58:03Z","timestamp":1610193483000},"page":"633.e9-633.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study"],"prefix":"10.1016","volume":"27","author":[{"given":"Amy K.","family":"Feehan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cruz","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Garcia-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eboni G.","family":"Price-Haywood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Pevey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Seoane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2020.12.029_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.11606\/s1518-8787.2020054002643","article-title":"Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil","volume":"54","author":"Amorim Filho","year":"2020","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.cmi.2020.12.029_bib2","first-page":"2020","article-title":"Early plateau of SARS-CoV-2 seroprevalence identified by tripartite immunoassay in a large population","author":"Emmenegger","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib3","first-page":"2020","article-title":"Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors","author":"Erikstrup","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib4","first-page":"2020","article-title":"Far away from herd immunity to SARS-CoV-2: results from a survey in healthy blood donors in South Eastern Italy","author":"Fiore","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib5","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-020-18468-8","article-title":"SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood","volume":"11","author":"Ng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2020.12.029_bib6","first-page":"2020","article-title":"SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak","author":"Valenti","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib7","first-page":"2020","article-title":"Covid-19 Seroprevalence rate in healthy blood donors from a community under strict lockdown measures","author":"Sughayer","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib8","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285","article-title":"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020","volume":"25","author":"Fischer","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2020.12.029_bib9","first-page":"2020","article-title":"Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study","author":"Doi","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib10","article-title":"Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City","author":"Stadlbauer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2020.12.029_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.4130","article-title":"Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, march 23\u2013may 12, 2020","author":"Havers","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2020.12.029_bib12","doi-asserted-by":"crossref","first-page":"e1390","DOI":"10.1016\/S2214-109X(20)30387-9","article-title":"SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys","volume":"8","author":"Hallal","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.cmi.2020.12.029_bib13","first-page":"2020","article-title":"Seroprevalence of COVID-19 virus infection in Guilan province, Iran","author":"Shakiba","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib14","first-page":"2020","article-title":"Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event","author":"Streeck","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8279","article-title":"Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles county, California","author":"Sood","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2020.12.029_bib16","first-page":"2020","article-title":"A\u00a0population-based study of the prevalence of COVID-19 infection in Espirito Santo, Brazil: methodology and results of the first stage","author":"Gomes","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00941-20","article-title":"Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho","volume":"58","author":"Bryan","year":"2020","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2020.12.029_bib18","first-page":"2020","article-title":"COVID-19 antibody seroprevalence in Santa Clara county, California","author":"Bendavid","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2488-1","article-title":"Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo","author":"Lavezzo","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cmi.2020.12.029_bib20","article-title":"Seroprevalence of SARS-CoV-2 significantly varies with age: preliminary results from a mass population screening","author":"Pagani","year":"2020","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2020.12.029_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31483-5","article-title":"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study","author":"Pollan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.12.029_bib22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.15585\/mmwr.mm6929e2","article-title":"Estimated community seroprevalence of SARS-CoV-2 antibodies \u2013 two Georgia counties, April 28\u2013May 3, 2020","volume":"69","author":"Biggs","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2020.12.029_bib23","article-title":"Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland","author":"Perez-Saez","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2020.12.029_bib24","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41591-020-0992-3","article-title":"Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil","volume":"26","author":"Silveira","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2020.12.029_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(20)31304-0","article-title":"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study","volume":"396","author":"Stringhini","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2020.12.029_bib26","first-page":"2020","article-title":"SARS-CoV-2 seroprevalence in the municipality of Sao Paulo, Brazil, ten weeks after the first reported case","author":"Tess","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.cmi.2020.12.029_bib27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.cmi.2020.07.013","article-title":"Low prevalence of active COVID-19 in Slovenia: a nationwide population study of a probability-based sample","volume":"26","author":"Maver Vodi\u010dar","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2020.12.029_bib28","doi-asserted-by":"crossref","DOI":"10.3201\/eid2611.203029","article-title":"Seroprevalence of SARS-CoV-2 and infection fatality ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020","volume":"26","author":"Feehan","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2020.12.029_bib29","article-title":"Racial and workplace disparities in seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA","volume":"27","author":"Feehan","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2020.12.029_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239235","article-title":"Clinical, laboratory and radiological characteristics and outcomes of novel coronavirus (SARS-CoV-2) infection in humans: a systematic review and series of meta-analyses","volume":"15","author":"Borges do Nascimento","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2020.12.029_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003358","article-title":"Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and\/or taste in a community-based population in London, UK: an observational cohort study","volume":"17","author":"Makaronidis","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2020.12.029_bib32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20307898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X20307898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:27:44Z","timestamp":1761118064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X20307898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1198743X20307898"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2020.12.029","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2020.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}